ASX:OVN

Stock Analysis Report

Executive Summary

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Oventus Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OVN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.7%

OVN

-1.3%

AU Medical Equipment

0.02%

AU Market


1 Year Return

106.7%

OVN

45.9%

AU Medical Equipment

14.6%

AU Market

Return vs Industry: OVN exceeded the Australian Medical Equipment industry which returned 45.9% over the past year.

Return vs Market: OVN exceeded the Australian Market which returned 14.6% over the past year.


Shareholder returns

OVNIndustryMarket
7 Day9.7%-1.3%0.02%
30 Day55.0%-0.1%0.2%
90 Day-1.6%7.7%5.4%
1 Year109.3%106.7%48.0%45.9%19.7%14.6%
3 Year2.9%1.6%82.1%74.2%38.7%20.2%
5 Yearn/a121.2%103.8%50.6%17.1%

Price Volatility Vs. Market

How volatile is Oventus Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oventus Medical undervalued compared to its fair value and its price relative to the market?

8.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OVN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OVN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OVN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: OVN is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OVN is overvalued based on its PB Ratio (9.4x) compared to the AU Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Oventus Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oventus Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Oventus Medical performed over the past 5 years?

-32.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVN is currently unprofitable.

Growing Profit Margin: OVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVN is unprofitable, and losses have increased over the past 5 years at a rate of -32.5% per year.

Accelerating Growth: Unable to compare OVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).


Return on Equity

High ROE: OVN has a negative Return on Equity (-106.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Oventus Medical's financial position?


Financial Position Analysis

Short Term Liabilities: OVN's short term assets (A$4.4M) exceed its short term liabilities (A$1.5M).

Long Term Liabilities: OVN's short term assets (A$4.4M) exceed its long term liabilities (A$75.9K).


Debt to Equity History and Analysis

Debt Level: OVN is debt free.

Reducing Debt: OVN had no debt 5 years ago.


Balance Sheet

Inventory Level: OVN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if OVN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OVN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OVN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -15.1% each year


Next Steps

Dividend

What is Oventus Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OVN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Chris Hart 0

1.5yrs

Tenure

AU$448,602

Compensation

Dr. Christopher Patrick Hart, also known as Chris, has been Chief Executive Officer and Managing Director of Oventus Medical Limited since September 2018. Dr. Hart is the Co-Founder of Oventus Medical Limi ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD297.66K) is about average for companies of similar size in the Australian market ($USD251.50K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Hart
Co-Founder1.5yrsAU$448.60k20.33% A$17.4m
Daniel Parry
Chief Financial Officer2.2yrsAU$267.56kno data
Robin Randolph
Senior Vice President of Sales0.08yrsAU$300.10kno data
Stephen Denaro
Company Secretary & Director0yrsAU$26.57k0.12% A$101.1k
Greg Eaton
Vice President Sales0yrsno datano data

1.8yrs

Average Tenure

Experienced Management: OVN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Christopher Hart
Co-Founder1.5yrsAU$448.60k20.33% A$17.4m
Stephen Denaro
Company Secretary & Director0yrsAU$26.57k0.12% A$101.1k
Richard Bogan
Member of Medical Technology Advisory Board1.4yrsno datano data
Melvyn Bridges
Non-Executive Chairman4.4yrsAU$85.86k1.06% A$906.9k
Susan MacLeman
Independent Non-Executive Director4.3yrsAU$60.86k0.032% A$27.2k
Lee Surkin
Member of Medical Technology Advisory Board1.4yrsno datano data
Jerrold Kram
Member of Medical Technology Advisory Board1.4yrsno datano data
Mark Hickey
Member of Medical Technology Advisory Board1.4yrsno datano data
Mark Rasmus
Member of Medical Technology Advisory Board1.4yrsno datano data
Daniel Brown
Member of Medical Technology Advisory Board1.4yrsno datano data

1.4yrs

Average Tenure

69yo

Average Age

Experienced Board: OVN's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.


Top Shareholders

Company Information

Oventus Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oventus Medical Limited
  • Ticker: OVN
  • Exchange: ASX
  • Founded: 2015
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$85.497m
  • Shares outstanding: 130.53m
  • Website: https://o2vent.com

Location

  • Oventus Medical Limited
  • 1 Swann Road
  • Suite 1
  • Indooroopilly
  • Queensland
  • 4068
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OVNCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJul 2016
OVNASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJul 2016

Biography

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. The company offers O2Vent Optima, a customized 3D-printed nylon oral appliance for OSA patients; and ExVent, an optional valve accessory that is inserted into the front oral airway of the O2Vent Optima or Winged device. It also develops O2Vent ONEPAP and O2Vent Connect products. The company was incorporated in 2015 and is headquartered in Indooroopilly, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 10:56
End of Day Share Price2020/02/24 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.